HCM
PGNX

Highbridge Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Highbridge Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-11,800
Closed -$87K – 2120
2017
Q3 		$87K Sell
11,800
-41,300
-78% -$262K ﹤0.01% 1478
2017
Q2 		$360K Buy
+53,100
New +$392K 0.01% 885
2015
Q4 		– Sell
-60,600
Closed -$347K – 1940
2015
Q3 		$347K Buy
60,600
+39,700
+190% +$305K 0.01% 1184
2015
Q2 		$156K Buy
+20,900
New +$126K ﹤0.01% 1317

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return

Highbridge Capital Management's PGNX Position: Q4 2016 in Review

Highbridge Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2016, closing a stake of 63,548 shares — an estimated $402K sold.

Highbridge Capital Management first reported a position in PGNX in Q2 2013 and held it in 7 quarters. The position peaked at $1.34M in Q3 2013. 126 funds tracked by Wall St. Rank hold PGNX as of Q4 2016.

  • Highbridge Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 63,548 Progenics Pharmaceuticals Inc shares in Q4 2016, an estimated $402K.
  • Highbridge Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 7 quarters.
  • Highbridge Capital Management's Progenics Pharmaceuticals Inc position peaked at $1.34M in Q3 2013.
  • 126 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.